Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 6/20 | 0.38 |
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3432105 | 0.88 | POLB (0.42) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL28609634 | 0.88 | POLB (0.42) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL5853865 | 0.83 | AOC3 (0.41) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL5853862 | 0.83 | AOC3 (0.41) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL3144258 | 0.82 | LMNA (0.48) | AOC3LMNAHRH1HTR2ATAAR1 | |
| SCHEMBL28607657 | 0.82 | LMNA (0.48) | AOC3LMNAHRH1HTR2ATAAR1 | |
| SCHEMBL16774656 | 0.81 | TRPA1 (0.48) | LMNAHRH1HTR2ATAAR1RIPK1 | |
| SCHEMBL3022300 | 0.81 | AOC3 (0.42) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL21625270 | 0.81 | AOC3 (0.42) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL21308579 | 0.81 | AOC3 (0.42) | AOC3LMNAHRH1HTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350060-B2 | 2-amino-bicyclo[3.1.0] hexane-2, 6-dicarboxylic ester derivative | Taisho Pharamceutical Co., Ltd. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8258133-B2 | 2-amino-bicyclo[3.1.0]hexane-2, 6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20120028982-A1 | 2-AMINO-BICYCLO[3.1.0]HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120004232-A1 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| US-8076502-B2 | 2-amino-bicyclo(3.1.0) hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICALS CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-8039647-B2 | 2-amino-bicyclo (3.1.0) hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-7960579-B2 | 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-2287147-A2 | 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20100298561-A1 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-7731941-B2 | Staining composition for staining an ophthalmic membrane | NATIONAL UNIVERSITY CORPORATION KYUSHU UNIVERSITY (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20050119345-A1 | 6-Fluorobicyclo[3.1.0]hexane derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| CN-1610557-A | 6-fluorobicyclo [3.1.0] hexane derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-04-27 | — | — | CN | disclosed |
| EP-1459765-A1 | 6-FLUOROBICYCLO 3.1.0 HEXANE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20030212116-A1 | Heterocyclic imino compounds and fungicides and insecticides for agricultural and horitcultural use | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1243580-A1 | HETEROCYCLIC IMINO COMPOUNDS AND FUNGICIDES AND INSECTICIDES FOR AGRICULTURAL AND HORTICULTURAL USE | Nissan Chemical Industries, Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0414200-B1 | Salts of optically active 4-hydroxy-8-(3-lower alkoxy-4-phenylsulfinylphenyl)pyrazolo [1,5-a]-1,3,5-triazines and a process for production thereof | OTSUKA PHARMA CO LTD (JP) | 1995-08-02 | — | — | EP | disclosed |
| CN-1028528-C | Salts of optically active 4-hydroxy-8-(3-lower alkoxy-4-phenylsulfinylphenyl) pyrazolo [1,5-a]-1,3,5-triazines | OTSUKA PHARMA CO LTD (JP) | 1995-05-24 | — | — | CN | disclosed |
| US-5137887-A | Xanthine oxidase inhibitors, antipodagric agents | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1992-08-11 | — | — | US | disclosed |
| CN-1049664-A | Optically active 4-hydroxyl-8-(3-low-alkoxy-4-phenyl sulfinyl phenyl) pyrazolo [1,5-α]-1,3,5-triazines salt and method for making thereof | OTSUKA PHARMA CO LTD (JP) | 1991-03-06 | — | — | CN | disclosed |
| EP-0414200-A2 | Salts of optically active 4-hydroxy-8-(3-lower alkoxy-4-phenylsulfinylphenyl)pyrazolo [1,5-a]-1,3,5-triazines and a process for production thereof | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119345-A1 | 6-Fluorobicyclo[3.1.0]hexane derivatives | GRM1, GRM2, GRM6 | AOC3 1715/4885LMNA 4553/4885HRH1 84/4885 |
| US-20030212116-A1 | Heterocyclic imino compounds and fungicides and insecticides for agricultural and horitcultural use | DDT, CBR3, CYP1B1 | AOC3 157/4885LMNA 3254/4885HRH1 543/4885 |
| US-20120028982-A1 | 2-AMINO-BICYCLO[3.1.0]HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | GRIK4, GRIN2D, GRIN2C | AOC3 1391/4885LMNA 4460/4885HRH1 147/4885 |
| US-20100298561-A1 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | GRIK4, GRIN2D, GRIN2C | AOC3 1393/4885LMNA 4565/4885HRH1 136/4885 |
| US-20120004232-A1 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | GRIK4, GRIN2D, GRIN2C | AOC3 1393/4885LMNA 4565/4885HRH1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.